BofA analyst Geoff Meacham downgraded Lyell Immunopharma (LYEL) to Underperform from Buy with a price target of $1, down from $6.
Education
About Us
Working with TipRanks
Follow Us
BofA analyst Geoff Meacham downgraded Lyell Immunopharma (LYEL) to Underperform from Buy with a price target of $1, down from $6.